Homocysteine is an aminoacid derived from the metabolism of dietary methionine (Figure 1) 4 . Conversion of methionine to homocysteine is an essential, ubiquitous component of intracellular metabolism which liberates methyl groups required for the synthesis of DNA, steroid hormones and some proteins. In plasma, most of the homocysteine is protein bound, with the remaining free homocysteine existing in reduced and oxidized forms 5 . In the laboratory total plasma homocysteine concentrations are usually measured by high-performance liquid chromatography 6 , but a recently introduced immunoassay offers a rapid, accurate assessment more suitable for routine clinical use 7 .
Normal levels of total plasma homocysteine vary between 5 and 15 mmol/L. Mutations in the enzymes involved in homocysteine metabolism, and de®ciencies of vitamins B 6 , B 12 and folic acid (co-factors for these enzymes), are associated with hyperhomocysteinaemia 4,8 . The 677C?T mutation in the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR), renders the enzyme thermolabile and functionally impaired 9 . Homozygosity for 677T MTHFR is found in approximately 15% of European whites, and is associated with a 2±3 mmol/L increase in homocysteine concentrations 10 . Dietary factors also have a major in¯uence on levels of homocysteine. Oral methionine, derived from dietary protein, induces short-term increments in homocysteine concentrations 11 , and in elderly populations low levels of B vitamins may be the primary determinant of raised plasma homocysteine 12 . Hyperhomocysteinaemia is also more prevalent amongst patients with renal impairment, recipients of renal and heart transplants and patients treated with drugs such as methotrexate which interfere with folate metabolism 8,13,14 .
HOMOCYSTINURIA AND VASCULAR DISEASE
The possible clinical importance of homocysteine was ®rst recognized in the 1960s, after description of the rare metabolic disorder homocystinuria. Affected children, who have severe hyperhomocysteinaemia (plasma concentrations >100 mmol/L), develop widespread premature atherosclerosis 15 . If untreated, they usually die of vascular complications such as pulmonary embolism, myocardial infarction, cerebrovascular accidents, and peripheral arterial thromboses 16, 17 . The vascular pathology is similar to that of conventional adult atherosclerosis, although intimal (1) Trans-methylation: conversion of methionine to homocysteine, thereby transferring methyl group to other species (R). (2) Trans-sulphuration: irreversible conversion of homocysteine to cysteine: via rate limiting enzyme cystathionine-b-synthase, with vitamin B 6 as essential co-factor.
(3) Re-methylation: regeneration of methionine from homocysteine: catabolized by methionine synthase, with 5,10-methylenetetrahydrofolate (MTHF, a form of folic acid) and vitamin B 12 as essential co-factors. (4) Regeneration of MTHF from tetrahydrofolate (THF), catabolized by enzyme 5,10-methylene-tetrahydrofolate reductase thickening and ®brous plaque are more common and there is a strong propensity for intravascular thrombosis 16 . Restriction of dietary methionine intake together with B vitamin supplementation (pyridoxine, folate and B 12 ) is effective in lowering homocysteine levels in some children with homocystinuria 17 . Observations that these treatment regimens substantially reduce cardiovascular risk in homocystinuric patients 17 support the view that raised homocysteine concentrations have a causal role in the vascular pathology of homocystinuria.
HOMOCYSTEINE AND RISK OF VASCULAR DISEASE IN ADULTS
Recognition that children with homocystinuria develop aggressive premature vascular disease led to the hypothesis that mild-to-moderate increases in plasma homocysteine might contribute to the development and progression of atherosclerosis in adults. This hypothesis has now been evaluated in over thirty cross-sectional and prospective studies involving more than 10 000 individuals 18, 19 . The results have been remarkably consistent. Raised plasma homocysteine is an independent risk factor for peripheral vascular, cerebrovascular, and coronary heart disease. The increased risk of CHD associated with homocysteine is additive to that of conventional vascular risk factors 20 , and is present even within the normal range for homocysteine 21 . In North American and European populations, a 5 mmol/L increase in homocysteine concentrations has been judged equivalent to an 0.6 mmol/L rise in total cholesterol, with raised homocysteine contributing to 10% of population CHD risk 18 .
DIFFERENCES IN HOMOCYSTEINE BETWEEN PATIENT GROUPS
Observations that plasma homocysteine is raised in patients with renal failure and in transplant recipients suggest that homocysteine may contribute to the widespread atherosclerosis and the high incidence of cardiovascular events seen in these patients 13, 14 . Plasma homocysteine concentrations vary not only between patient groups but also between countries, and in Europe are closely related to national age-standardized cardiovascular disease mortality rates 22 . Although few studies have been undertaken in nonwhite populations, recent data show that Indian Asians have higher plasma homocysteine concentrations than European whitesÐa difference that might contribute to their higher CHD mortality rates 23, 24 . Conversely, South African blacks have more effective homocysteine metabolism and lower homocysteine levels than South African whites, which may explain their relative resistance to CHD despite a high prevalence of obesity, hypertension and smoking 25 .
MECHANISMS LINKING HOMOCYSTEINE TO VASCULAR DISEASE
There is continuing uncertainty whether homocysteine has a causal role in the development of atherosclerosis or is simply a marker for increased vascular risk 26 . Evidence to support a direct role for homocysteine in the pathogenesis of vascular disease has emerged from studies showing a dynamic and inverse relationship between plasma homocysteine and vascular endothelial function. Acute hyperhomocysteinaemia is associated with rapid-onset vascular endothelial dysfunction, an early manifestation of atherosclerosis 27±31 . These observations are consistent with reports of dose and time dependent effects of homocysteine on endothelial cellular function in vitro 32±34 . Endothelial dysfunction can also be induced by the increments in plasma homocysteine that follow low-dose oral methionine, or dietary consumption of animal protein 29 . These ®ndings suggest that even diet-related increments in plasma homocysteine contribute to the development and progression of atherosclerosis.
The possible mechanisms linking homocysteine to endothelial dysfunction are summarized in Figure 2 . Homocysteine may exert its effects by promoting oxidative damage in endothelial cells, with the generation of superoxide anion radicals (O 2 7) and hydrogen peroxide (H 2 O 2 ) 32, 35 . Generation of free-radical superoxide anions may promote oxidation of low-density lipoprotein (LDL) and deactivation of nitric oxide 36 . Deactivation of nitric oxide, the major endothelium-derived vasodilator, may lead to vasoconstriction, platelet aggregation and monocyte adhesion, all of which promote atherosclerosis 36 presence of oxidant stress during hyperhomocysteinaemia is con®rmed by measurement of lipid peroxides 37, 38 and also by the effect of the antioxidant vitamin C, which reverses homocysteine-induced endothelial dysfunction 28, 31 . More recent in-vitro studies have suggested that homocysteine reacts with amine groups on proteins, possibly producing abnormalities of enzyme or receptor function 39, 40 . The in-vivo signi®cance of this protein homocysteinylation remains to be determined.
EFFECTS OF HOMOCYSTEINE LOWERING
Folic acid and vitamin B 12 are essential cofactors for the remethylation of homocysteine to methionine, and dietary supplementation with these B vitamins provides an effective means to lower concentrations of plasma homocysteine 41 .
In adults, dietary folic acid at doses of 0.5±5 mg/day lowers homocysteine concentrations by about 25%. Additional oral vitamin B 12 results in a further 7% reduction in plasma homocysteine, when given at a dose of 0.5 mg/day. Epidemiological data suggest that a decrease in homocysteine concentrations of this magnitude might reduce risk of cardiovascular events in patients with CHD by as much as 15±30% 42 . However, at present little is known about the possible bene®cial vascular effects of lowering homocysteine in man. Recent studies have examined the effects of homocysteine lowering on surrogate markers of atherosclerosis. In healthy volunteers and in patients with CHD, B vitamin supplementation is associated with an improvement in endothelium-dependent dilatation and in serum markers of endothelial injury 7,43±46 . Furthermore, amongst healthy siblings of patients with premature atherosclerosis, homocysteine lowering reduces the occurrence of abnormal exercise tests to an extent consistent with a decreased risk of future atherosclerotic coronary events 47 . More conclusive evidence on the causal role of homocysteine in vascular disease will emerge from large-scale randomized placebo-controlled intervention trials now underway. The aim is to discover whether homocysteine lowering will reduce the incidence of major cardiovascular events in patients with CHD 42 . The results of these intervention trials, expected within 5 years, are required before we could advocate routine screening of patients with vascular disease for homocysteine levels, or widespread use of vitamin therapy for the prevention of cardiovascular disease.
CONCLUSIONS
Epidemiological studies provide convincing and consistent evidence that raised homocysteine is a risk factor for vascular disease, including CHD, in adults. Physiological studies show that a high plasma homocysteine induces vascular endothelial dysfunction, so the relationship between homocysteine and vascular disease may well be causal. However, at present there are no data to show that lowering homocysteine will reduce major cardiovascular endpoints. V o l u m e 9 4 J a n u a r y 2 0 0 1
